Ventricular tachycardia (VT), and its occurrence, is still one of the main reasons for sudden cardiac death and, therefore, for increased mortality and morbidity foremost in patients with structural heart [Kahle A-K, Jungen C, Alken F-A, Scherschel K, Willems S, Pürerfellner H et al. Management of ventricular tachycardia in patients with ischaemic cardiomyopathy: contemporary armamentarium. Europace 2022;24:538–51]. Catheter ablation has become a safe and effective treatment option in patients with recurrent VT [Cronin EM, Bogun FM, Maury P, Peichl P, Chen M, Namboodiri N et al. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Heart Rhythm 2020;17:e2–154]. Previous and current guidelines provide guidance on indication for VT ablation and risk assessment and evaluation of underlying disease. However, no uniform recommendation is provided regarding procedural strategies, timing of ablation, and centre setting. Therefore, these specifics seem to differ largely, and recent data are sparse. This physician-based European Heart Rhythm Association survey aims to deliver insights on not only infrastructural settings but also procedural specifics, applied technologies, ablation strategies, and procedural endpoints. Therefore, these findings might deliver a real-world scenario of VT management and potentially are of guidance for other centres.

中文翻译：

---

室性心动过速的管理：对中心设置、程序工作流程、终点和指南实施的见解——来自 EHRA 调查的结果

室性心动过速 (VT) 及其发生仍然是心源性猝死的主要原因之一，因此，结构性心脏病患者的死亡率和发病率首先增加 [Kahle AK, Jungen C, Alken FA, Scherschel K, Willems S、Pürerfellner H 等人。缺血性心肌病患者室性心动过速的治疗：当代医疗设备。欧洲2022年；24：538–51]。导管消融已成为复发性 VT 患者安全有效的治疗选择 [Cronin EM、Bogun FM、Maury P、Peichl P、Chen M、Namboodiri N 等人。2019年HRS/EHRA/APHRS/LAHRS室性心律失常导管消融专家共识声明。心律 2020；17：e2–154]。以前和当前的指南提供了有关 VT 消融适应症以及风险评估和潜在疾病评估的指导。然而，对于手术策略、消融时间和中心设置，没有提供统一的建议。因此，这些细节似乎差异很大，而且最近的数据很少。这项以医生为基础的欧洲心律协会调查旨在不仅提供有关基础设施设置的见解，还提供有关手术细节、应用技术、消融策略和手术终点的见解。因此，这些发现可能会提供 VT 管理的真实场景，并可能为其他中心提供指导。